ES533930A0 - Un procedimiento para obtener un polidoma - Google Patents

Un procedimiento para obtener un polidoma

Info

Publication number: ES533930A0
Authority: ES; Spain
Prior art keywords: polydoma; procedure; obtaining
Prior art date: 1982-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

ES533930A

Other languages

English (en)

Other versions

ES8603080A1 (es

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hybritech Inc

Original Assignee

Hybritech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-04-12

Filing date

1984-07-02

Publication date

1985-12-01

1984-07-02 Application filed by Hybritech Inc filed Critical Hybritech Inc

1985-12-01 Publication of ES8603080A1 publication Critical patent/ES8603080A1/es

1985-12-01 Publication of ES533930A0 publication Critical patent/ES533930A0/es

Status Granted legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Optics & Photonics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

ES533930A 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma Granted ES533930A0 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US36778482A	1982-04-12	1982-04-12

Publications (2)

Publication Number	Publication Date
ES8603080A1 ES8603080A1 (es)	1985-12-01
ES533930A0 true ES533930A0 (es)	1985-12-01

Family

ID=23448582

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
ES521370A Granted ES521370A0 (es)	1982-04-12	1983-04-11	Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es)	1982-04-12	1983-12-12	Un procedimiento de inmunoensayo
ES533930A Granted ES533930A0 (es)	1982-04-12	1984-07-02	Un procedimiento para obtener un polidoma
ES533931A Expired ES8506091A1 (es)	1982-04-12	1984-07-02	Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es)	1982-04-12	1984-10-31	Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es)	1982-04-12	1984-12-18	Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es)	1982-04-12	1985-07-16	Un procedimiento para obtener un polidoma

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
ES521370A Granted ES521370A0 (es)	1982-04-12	1983-04-11	Un procedimiento para obtener un polidoma.
ES527963A Expired ES8503441A1 (es)	1982-04-12	1983-12-12	Un procedimiento de inmunoensayo

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
ES533931A Expired ES8506091A1 (es)	1982-04-12	1984-07-02	Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es)	1982-04-12	1984-10-31	Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es)	1982-04-12	1984-12-18	Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es)	1982-04-12	1985-07-16	Un procedimiento para obtener un polidoma

Country Status (11)

Country	Link
EP (1)	EP0105360A4 (es)
JP (2)	JPH0753119B2 (es)
AT (1)	AT394577B (es)
AU (1)	AU550486B2 (es)
CA (1)	CA1213229A (es)
CH (1)	CH672796A5 (es)
ES (7)	ES521370A0 (es)
FI (2)	FI834529L (es)
GB (4)	GB2128631B (es)
IT (1)	IT1219778B (es)
WO (1)	WO1983003679A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3177776B2 (ja) *	1988-09-27	2001-06-18	武田薬品工業株式会社	ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) *	1981-12-21	1994-03-08	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
CA1214123A (en) *	1983-01-20	1986-11-18	Masashi Matsui	Cell lines for use in the preparation of hybridoma cells
GB2148299B (en) *	1983-09-01	1988-01-06	Hybritech Inc	Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) *	1983-09-01	1992-01-22	Hybritech Incorporated	Antibody compositions of therapeutic agents having an extended serum half-life
JPH0617909B2 (ja) *	1984-04-23	1994-03-09	ボストンバイオメディカルリサーチインスティテュート，インコーポレイテッド	双特異性抗体決定子
NL8501219A (nl) *	1985-04-29	1986-11-17	Stichting Vrienden Van De Stic	Immunologisch complex, de bereiding en toepassing daarvan.
JP2635343B2 (ja)	1986-04-14	1997-07-30	ザ・ジェネラル・ホスピタル・コーポレーション	ヘテロ二官能性抗体および利用方法
US5453269A (en) *	1986-04-14	1995-09-26	The General Hospital Corporation	Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
FR2604092B1 (fr) *	1986-09-19	1990-04-13	Immunotech Sa	Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626413D0 (en) *	1986-11-05	1986-12-03	Gilliland L K	Antibodies
GB8626412D0 (en) *	1986-11-05	1986-12-03	Clark M R	Antibodies
US5053226A (en) *	1987-07-15	1991-10-01	Board Of Regents, The University Of Texas System	Monoclonal antibodies binding platinum complexes
CA1338518C (en) *	1987-09-23	1996-08-13	Joyce M. Zarling	Antibody heteroconjugates for the killing of hiv-infected cells
GB2218100A (en) *	1988-03-02	1989-11-08	Erling Sundrehagen	Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) *	1988-03-15	1990-01-09	Synbiotics Corporation	Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en)	1988-04-04	1996-12-10	General Hospital Corporation	Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) *	1988-04-04	1994-12-13	The General Hospital Corporation	Composition and method for acceleration of clot lysis
JPH02196799A (ja) *	1988-04-08	1990-08-03	Agency Of Ind Science & Technol	抗ヒト癌蛋白複合体
US5851527A (en) *	1988-04-18	1998-12-22	Immunomedics, Inc.	Method for antibody targeting of therapeutic agents
IT1235349B (it) *	1988-12-23	1992-06-30	Biodata Spa	Saggio immunologico per determinazioni in fase omogenea
CA2006408A1 (en) *	1988-12-27	1990-06-27	Susumu Iwasa	Bispecific monoclonal antibody, its production and use
US5217713A (en) *	1988-12-27	1993-06-08	Takeda Chemical Industries, Ltd.	Cytotoxic bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) *	1989-03-30	1990-10-18	Board Of Regents, The University Of Texas System	Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) *	1989-09-21	1994-10-28	Immunotech Partners	Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
EP0515571B1 (en) *	1990-02-16	1998-12-02	Boston Biomedical Research Institute	Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (es) *	1990-04-02	1993-09-01	Takeda Pharm Industry Co Ltd
WO1992019973A1 (en) *	1991-04-26	1992-11-12	Surface Active Limited	Novel antibodies, and methods for their use
GB9316369D0 (en) *	1993-08-06	1993-09-22	Surface Active Ltd	Diagnostic method
US5541110A (en)	1994-05-17	1996-07-30	Bristol-Myers Squibb	Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) *	1994-10-18	1994-12-07	Surface Active Ltd	Biosensor
CA2266341A1 (en) *	1996-09-20	1998-03-26	The General Hospital Corporation	Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US20020132274A1 (en)	2001-01-17	2002-09-19	Nevalainen Marja T.	Diagnostic and monitorings methods for cancer
EP2353611B1 (en)	2002-07-31	2015-05-13	Seattle Genetics, Inc.	Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PT2489364E (pt)	2003-11-06	2015-04-16	Seattle Genetics Inc	Compostos de monometilvalina conjugados com anticorpos
US7932242B2 (en)	2004-03-16	2011-04-26	Temple University - Of The Commonwealth System Of Higher Education	Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
CA2586909A1 (en)	2004-11-12	2006-12-14	Seattle Genetics, Inc.	Auristatins having an aminobenzoic acid unit at the n terminus
EP2511299A1 (en)	2005-04-19	2012-10-17	Seattle Genetics, Inc.	Humanized anti-CD70 binding agents and uses thereof
WO2007011968A2 (en)	2005-07-18	2007-01-25	Seattle Genetics, Inc.	Beta-glucuronide-linker drug conjugates
PT2099823E (pt)	2006-12-01	2014-12-22	Seattle Genetics Inc	Agentes de ligação ao alvo variantes e suas utilizações
WO2008091740A2 (en)	2007-01-22	2008-07-31	Genentech, Inc.	Polyelectrolyte precipitation and purification of antibodies
EP2282773B2 (en)	2008-05-02	2025-03-05	Seagen Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en)	2010-04-22	2011-10-27	Boston Medical Center Corporation	Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en)	2012-12-04	2016-05-31	Massachusetts Institute Of Technology	Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US10201614B2 (en)	2013-03-15	2019-02-12	Zymeworks Inc.	Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6473418B2 (ja)	2013-10-10	2019-02-20	幸成加藤	抗ポドプラニン抗体
EP3086815B1 (en)	2013-12-27	2022-02-09	Zymeworks Inc.	Sulfonamide-containing linkage systems for drug conjugates
US10450378B2 (en)	2014-09-17	2019-10-22	Zymeworks Inc.	Cytotoxic and anti-mitotic compounds, and methods of using the same
TWI618697B (zh)	2015-11-03	2018-03-21	財團法人工業技術研究院	化合物、連接子－藥物、及配體－藥物耦合體
CN109843919A (zh)	2016-03-25	2019-06-04	西雅图基因公司	用于制备聚乙二醇化的药物-接头及其中间体的方法
US10918627B2 (en)	2016-05-11	2021-02-16	Massachusetts Institute Of Technology	Convergent and enantioselective total synthesis of Communesin analogs
CN110430901B (zh)	2017-03-24	2024-08-16	西雅图基因公司	制备葡糖苷酸药物-接头及其中间体的方法
US11932650B2 (en)	2017-05-11	2024-03-19	Massachusetts Institute Of Technology	Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
US10869888B2 (en)	2018-04-17	2020-12-22	Innovative Cellular Therapeutics CO., LTD.	Modified cell expansion and uses thereof
US12240915B2 (en)	2018-08-30	2025-03-04	Innovative Cellular Therapeutics Holdings, Ltd.	Chimeric antigen receptor cells for treating solid tumor
WO2020047306A1 (en)	2018-08-30	2020-03-05	Innovative Cellular Therapeutics CO., LTD.	Chimeric antigen receptor cells for treating solid tumor
CN119770674A (zh)	2019-05-10	2025-04-08	武田药品工业株式会社	抗体药物缀合物
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US12076343B2 (en)	2020-02-19	2024-09-03	Innovative Cellular Therapeutics Holdings, Ltd.	Engineered safety in cell therapy
US12043654B2 (en)	2020-06-02	2024-07-23	Innovative Cellular Therapeutics Holdings, Ltd.	Anti-GCC antibody and CAR thereof for treating digestive system cancer
IL302390A (en)	2020-11-09	2023-06-01	Takeda Pharmaceuticals Co	Drug antibody conjugates
WO2022182415A1 (en)	2021-02-24	2022-09-01	Massachusetts Institute Of Technology	Himastatin derivatives, and processes of preparation thereof, and uses thereof
EP4362977A1 (en)	2021-06-29	2024-05-08	Seagen Inc.	Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4130634A (en) *	1974-03-15	1978-12-19	University Of Illinois Foundation	Method for detecting and quantifying antigens
US4331647A (en) *	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) *	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4474893A (en) *	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies

1983
- 1983-04-11 ES ES521370A patent/ES521370A0/es active Granted
- 1983-04-11 CA CA000425558A patent/CA1213229A/en not_active Expired
- 1983-04-12 AT AT0901883A patent/AT394577B/de not_active IP Right Cessation
- 1983-04-12 AU AU15559/83A patent/AU550486B2/en not_active Expired
- 1983-04-12 FI FI834529A patent/FI834529L/fi not_active Application Discontinuation
- 1983-04-12 WO PCT/US1983/000525 patent/WO1983003679A1/en not_active Ceased
- 1983-04-12 FI FI900212A patent/FI900212A7/fi not_active Application Discontinuation
- 1983-04-12 CH CH6700/83A patent/CH672796A5/de not_active IP Right Cessation
- 1983-04-12 EP EP19830901672 patent/EP0105360A4/en not_active Ceased
- 1983-04-12 GB GB08332646A patent/GB2128631B/en not_active Expired
- 1983-04-12 IT IT20548/83A patent/IT1219778B/it active
- 1983-12-12 ES ES527963A patent/ES8503441A1/es not_active Expired
1984
- 1984-07-02 ES ES533930A patent/ES533930A0/es active Granted
- 1984-07-02 ES ES533931A patent/ES8506091A1/es not_active Expired
- 1984-10-31 ES ES537257A patent/ES8606655A1/es not_active Expired
- 1984-12-18 ES ES538727A patent/ES8604424A1/es not_active Expired
1985
- 1985-07-16 ES ES545247A patent/ES8607386A1/es not_active Expired
- 1985-12-09 GB GB08530308A patent/GB2168998B/en not_active Expired
- 1985-12-09 GB GB08530309A patent/GB2169921B/en not_active Expired
- 1985-12-09 GB GB08530310A patent/GB2167086B/en not_active Expired
1987
- 1987-01-05 JP JP62000342A patent/JPH0753119B2/ja not_active Expired - Lifetime
1994
- 1994-02-10 JP JP6016728A patent/JP2562002B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES8603080A1 (es)	1985-12-01
ES527963A0 (es)	1985-02-16
GB2168998A (en)	1986-07-02
GB8530308D0 (en)	1986-01-22
JP2562002B2 (ja)	1996-12-11
ES8503441A1 (es)	1985-02-16
FI900212A0 (fi)	1990-01-15
GB8332646D0 (en)	1984-01-11
ES538727A0 (es)	1986-02-01
IT1219778B (it)	1990-05-24
ES8504461A1 (es)	1985-04-16
WO1983003679A1 (en)	1983-10-27
JPH0753119B2 (ja)	1995-06-07
ES537257A0 (es)	1986-04-01
FI834529A7 (fi)	1983-12-09
GB2168998B (en)	1987-03-04
AT394577B (de)	1992-05-11
FI834529A0 (fi)	1983-12-09
GB2169921A (en)	1986-07-23
GB2169921B (en)	1987-03-04
GB2128631B (en)	1987-02-25
ATA901883A (de)	1991-10-15
CA1213229A (en)	1986-10-28
FI834529L (fi)	1983-12-09
GB8530309D0 (en)	1986-01-22
ES8607386A1 (es)	1986-05-16
GB2167086B (en)	1987-03-04
JPS6312276A (ja)	1988-01-19
ES521370A0 (es)	1985-04-16
ES8604424A1 (es)	1986-02-01
GB2128631A (en)	1984-05-02
EP0105360A1 (en)	1984-04-18
EP0105360A4 (en)	1986-07-08
ES8606655A1 (es)	1986-04-01
AU1555983A (en)	1983-11-04
CH672796A5 (es)	1989-12-29
AU550486B2 (en)	1986-03-20
FI900212A7 (fi)	1990-01-15
ES533931A0 (es)	1985-06-16
ES8506091A1 (es)	1985-06-16
IT8320548A0 (it)	1983-04-12
JPH0753600A (ja)	1995-02-28
GB8530310D0 (en)	1986-01-22
GB2167086A (en)	1986-05-21
ES545247A0 (es)	1986-05-16

Publication	Publication Date	Title
ES533930A0 (es)	1985-12-01	Un procedimiento para obtener un polidoma
ES500726A0 (es)	1982-03-01	Un procedimiento para preparar diaminopiridinas
ES532538A0 (es)	1985-07-16	Un procedimiento para preparar un derivado de carbostirilo
ES523195A0 (es)	1984-10-01	Un procedimiento para preparar alquil-glicosidos
ES537668A0 (es)	1985-09-16	Un procedimiento para preparar n-formil-3-fenoxi-1-azetidincarboxamidas
ES530024A0 (es)	1985-12-01	Un procedimiento para preparar derivados de pirazinona
ES527790A0 (es)	1985-07-16	Un procedimiento para preparar nuevos compuestos de cefem
ES500727A0 (es)	1982-01-16	Un procedimiento para preparar imidazo-piridinas
ES545270A0 (es)	1986-03-16	Un procedimiento para la obtencion de piridoindoles
ES528304A0 (es)	1985-08-01	Un procedimiento para preparar derivados de pirimidona
ES534297A0 (es)	1985-06-01	Un procedimiento para preparar derivados de cefem
ES519652A0 (es)	1984-03-16	Un procedimiento para obtener s-adenosil-metionina.
ES524245A0 (es)	1985-04-01	Procedimiento para obtener un polipeptido
ES523193A0 (es)	1984-10-01	Un procedimiento para preparar 3-fenoxi-1-azetidincarbo-xznmidas
MX163078B (es)	1991-08-15	Procedimiento mejorado para formar nitroparafinas
ES525007A0 (es)	1985-01-01	Un procedimiento para producir derivados de tiazol
ES539082A0 (es)	1986-05-16	Un procedimiento para preparar compuestos peptidicos sustituidos
ES527278A0 (es)	1985-04-16	Un procedimiento para obtener 2,5-anhidro-3,4,6-tri-o-acil-d-alonselenocarboxamida
ES526177A0 (es)	1985-05-01	Un procedimiento para preparar derivados de pirimidona
ES500464A0 (es)	1982-02-01	Un procedimiento para preparar 2-halogeno-acetanilidas
ES527108A0 (es)	1985-07-01	Un procedimiento para preparar 2-alcoxi-5-(piridinil) piridinas
ES527738A0 (es)	1985-11-16	Un procedimiento para preparar derivados de piridona
ES525647A0 (es)	1985-08-16	Un procedimiento para preparar compuestos de benzoilurea
ES518376A0 (es)	1984-08-01	Un procedimiento para preparar nuevas nitro-n-fenilpiridinaminas
ES527789A0 (es)	1984-12-01	Un procedimiento para preparar derivados de cicloalquenilo